Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Terminated NCT04499157

Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

Conditions: Open-angle Glaucoma, Visual Field

Sex: All
Ages: 20 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 15
Sponsor: Centre Hospitalier Universitaire, Amiens

Location: CHU Amiens Amiens

Summary

Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients. The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.

Eligibility Criteria

Inclusion Criteria: * diagnosis of GCAO defined by OCT RNFL alterations and visual fields defects * age between 20 and 80 years old * Well controled intra-ocular pressure under treatment (PIO\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04499157). StuddyBuddy aggregates publicly available trial information.